Literature DB >> 20378821

Genotype-phenotype correlation in X-linked Alport syndrome.

Mir Reza Bekheirnia1, Berenice Reed, Martin C Gregory, Kim McFann, Alireza Abdollah Shamshirsaz, Amirali Masoumi, Robert W Schrier.   

Abstract

Mutations in the COL4A5 gene cause X-linked Alport syndrome (XLAS). Understanding the correlation between clinical manifestations and the underlying mutations adds prognostic value to genetic testing, which is increasingly available. Our aim was to determine the association between genotype and phenotype in 681 affected male participants with XLAS from 175 US families. Hearing loss and ocular changes were present in 67 and 30% of participants, respectively. Average age of participants at onset of ESRD was 37 years for those with missense mutations, 28 years for those with splice-site mutations, and 25 years for those with truncating mutations (P < 0.0001). We demonstrated a strong relationship between mutation position and age at onset of ESRD, with younger age at onset of ESRD associated with mutations at the 5' end of the gene (hazard ratio 0.766 [95% confidence interval 0.694 to 0.846] per 1000 bp toward the 3' end; P < 0.0001). Affected participants with splice mutations or truncating mutations each had two-fold greater odds of developing eye problems than those with missense mutations; development of hearing impairment showed a similar trend. Hearing loss and ocular changes associated with mutations located closer to the 5; end of the gene. These strong genotype-phenotype correlations could potentially help in the evaluation and counseling of US families with XLAS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20378821      PMCID: PMC2865738          DOI: 10.1681/ASN.2009070784

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  32 in total

Review 1.  Alport syndrome.

Authors:  C E Kashtan; A F Michael
Journal:  Kidney Int       Date:  1996-11       Impact factor: 10.612

2.  Phenotypic and genotypic features of Alport syndrome in Chinese children.

Authors:  Fang Wang; Jie Ding; Shunhua Guo; Jiyun Yang
Journal:  Pediatr Nephrol       Date:  2002-11-14       Impact factor: 3.714

3.  Diagnosis of Alport syndrome without biopsy?

Authors:  Marie Claire Gubler
Journal:  Pediatr Nephrol       Date:  2006-12-02       Impact factor: 3.714

4.  Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.

Authors:  K E Heath; A Campos-Barros; A Toren; G Rozenfeld-Granot; L E Carlsson; J Savige; J C Denison; M C Gregory; J G White; D F Barker; A Greinacher; C J Epstein; M J Glucksman; J A Martignetti
Journal:  Am J Hum Genet       Date:  2001-10-04       Impact factor: 11.025

Review 5.  Alport syndrome. An inherited disorder of renal, ocular, and cochlear basement membranes.

Authors:  C E Kashtan
Journal:  Medicine (Baltimore)       Date:  1999-09       Impact factor: 1.889

6.  Common ancestry of three Ashkenazi-American families with Alport syndrome and COL4A5 R1677Q.

Authors:  D F Barker; J C Denison; C L Atkin; M C Gregory
Journal:  Hum Genet       Date:  1997-05       Impact factor: 4.132

7.  Alport retinopathy results from "severe" COL4A5 mutations and predicts early renal failure.

Authors:  Rachel Tan; Deb Colville; Yan Yan Wang; Lin Rigby; Judy Savige
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 8.237

8.  Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling.

Authors:  Oliver Gross; Kai-Olaf Netzer; Romy Lambrecht; Stefan Seibold; Manfred Weber
Journal:  Nephrol Dial Transplant       Date:  2002-07       Impact factor: 5.992

Review 9.  Molecular genetics of Alport syndrome.

Authors:  K Tryggvason; J Zhou; S L Hostikka; T B Shows
Journal:  Kidney Int       Date:  1993-01       Impact factor: 10.612

Review 10.  Familial hematuria due to type IV collagen mutations: Alport syndrome and thin basement membrane nephropathy.

Authors:  Clifford E Kashtan
Journal:  Curr Opin Pediatr       Date:  2004-04       Impact factor: 2.856

View more
  82 in total

Review 1.  Genetic basis of adult-onset nephrotic syndrome and focal segmental glomerulosclerosis.

Authors:  Jian Liu; Weiming Wang
Journal:  Front Med       Date:  2017-08-03       Impact factor: 4.592

2.  Poststreptococcal acute glomerulonephritis can be a risk factor for accelerating kidney dysfunction in Alport syndrome: a case experience.

Authors:  Yoshinori Araki; Azusa Kawaguchi; Nana Sakakibara; Yoshinobu Nagaoka; Tomohiko Yamamura; Tomoko Horinouchi; China Nagano; Naoya Morisada; Kazumoto Iijima; Kandai Nozu
Journal:  CEN Case Rep       Date:  2020-06-26

3.  X-linked Alport syndrome associated with a synonymous p.Gly292Gly mutation alters the splicing donor site of the type IV collagen alpha chain 5 gene.

Authors:  Xue Jun Fu; Kandai Nozu; Aya Eguchi; Yoshimi Nozu; Naoya Morisada; Akemi Shono; Mariko Taniguchi-Ikeda; Yuko Shima; Koichi Nakanishi; Igor Vorechovsky; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-11-18       Impact factor: 2.801

Review 4.  The collagenopathies: review of clinical phenotypes and molecular correlations.

Authors:  Rebekah Jobling; Rohan D'Souza; Naomi Baker; Irene Lara-Corrales; Roberto Mendoza-Londono; Lucie Dupuis; Ravi Savarirayan; L Ala-Kokko; Peter Kannu
Journal:  Curr Rheumatol Rep       Date:  2014-01       Impact factor: 4.592

5.  Detection of Splicing Abnormalities and Genotype-Phenotype Correlation in X-linked Alport Syndrome.

Authors:  Tomoko Horinouchi; Kandai Nozu; Tomohiko Yamamura; Shogo Minamikawa; Takashi Omori; Keita Nakanishi; Junya Fujimura; Akira Ashida; Mineaki Kitamura; Mitsuhiro Kawano; Wataru Shimabukuro; Chizuko Kitabayashi; Aya Imafuku; Keiichi Tamagaki; Koichi Kamei; Kenjirou Okamoto; Shuichiro Fujinaga; Masafumi Oka; Toru Igarashi; Akinori Miyazono; Emi Sawanobori; Rika Fujimaru; Koichi Nakanishi; Yuko Shima; Masafumi Matsuo; Ming Juan Ye; Yoshimi Nozu; Naoya Morisada; Hiroshi Kaito; Kazumoto Iijima
Journal:  J Am Soc Nephrol       Date:  2018-06-29       Impact factor: 10.121

6.  Improving mutation screening in familial hematuric nephropathies through next generation sequencing.

Authors:  Vincent Morinière; Karin Dahan; Pascale Hilbert; Marieline Lison; Said Lebbah; Alexandra Topa; Christine Bole-Feysot; Solenn Pruvost; Patrick Nitschke; Emmanuelle Plaisier; Bertrand Knebelmann; Marie-Alice Macher; Laure-Hélène Noel; Marie-Claire Gubler; Corinne Antignac; Laurence Heidet
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

7.  Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations.

Authors:  Johanna Stock; Johannes Kuenanz; Niklas Glonke; Joseph Sonntag; Jenny Frese; Burkhard Tönshoff; Britta Höcker; Bernd Hoppe; Markus Feldkötter; Lars Pape; Christian Lerch; Simone Wygoda; Manfred Weber; Gerhard-Anton Müller; Oliver Gross
Journal:  Pediatr Nephrol       Date:  2016-07-11       Impact factor: 3.714

8.  Identification of a novel COL4A5 mutation in a Chinese family with X-linked Alport syndrome using exome sequencing.

Authors:  Yi Guo; Jinzhong Yuan; Hui Liang; Jingjing Xiao; Hongbo Xu; Lamei Yuan; Kai Gao; Bin Wu; Yongchang Tang; Xiaorong Li; Hao Deng
Journal:  Mol Biol Rep       Date:  2014-02-13       Impact factor: 2.316

Review 9.  An update on the pathomechanisms and future therapies of Alport syndrome.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2012-08-18       Impact factor: 3.714

10.  Prognostic value of glomerular collagen IV immunofluorescence studies in male patients with X-linked Alport syndrome.

Authors:  Laura Massella; Concetta Gangemi; Kostas Giannakakis; Antonella Crisafi; Tullio Faraggiana; Chiara Fallerini; Alessandra Renieri; Andrea Onetti Muda; Francesco Emma
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-31       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.